Renaissance Capital logo

Apogee Therapeutics Priced, Nasdaq: APGE

Phase 1-ready biotech developing antibody therapies for inflammatory diseases.

Industry: Health Care

Latest Trade: $38.00 0.00 (0.0%)

First Day Return: +24.9%

Return from IPO: +123.5%

Industry: Health Care

We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Our two most advanced programs are APG777 and APG808, which we are initially developing for the treatment of AD and COPD, respectively. With our broad pipeline and depth of expertise, we believe we can deliver value and meaningful benefit to patients underserved by today’s standard of care. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Ra. Our earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, respectively, which we are initially developing for the treatment of AD. We were founded in 2022 by leading healthcare investors Fairmount Funds and Venrock Healthcare Capital, and we have exclusive development and commercialization rights to our programs through a strategic collaboration with Paragon Therapeutics.
more less
IPO Data
IPO File Date 06/22/2023
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 17.7
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/13/2023
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 17.7
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
TD Cowen
more
Company Data
Headquarters Waltham, MA, United States
Founded 2022
Employees 25
Website www.apogeetherapeutics.com

Apogee Therapeutics (APGE) Performance